We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Administration Routes and Doses of the Attenuated African Swine Fever Virus Strain PSA-1NH Influence Cross-Protection of Pigs against Heterologous Challenge.
- Authors
Vlasov, Mikhail; Sindryakova, Irina; Kudryashov, Dmitriy; Morgunov, Sergey; Kolbasova, Olga; Lyska, Valentina; Zhivoderov, Sergey; Pivova, Elena; Balyshev, Vladimir; Namsrayn, Sanzhi; Sevskikh, Timofey; Sereda, Alexey; Kolbasov, Denis
- Abstract
Simple Summary: African swine fever (ASF) is a lethal hemorrhagic disease of Suidae, i.e., domestic pigs and wild boars, caused by African swine fever virus (ASFV). The development of cross-protective vaccines against ASF is imperative for effective disease control, particularly in regions where ASF is endemic, potentially featuring multiple circulating ASFV isolates. It was shown that the intranasal administration of a low dose of ASFV-PSA-1NH (immunotype IV, genotype I) to pigs led to minimal manifestation of clinical signs of ASF and the formation of a high level of protection against the heterologous strain ASFV-Stavropol 01/08 (seroimmunotype VIII, genotype II). African swine fever (ASF) is a lethal hemorrhagic disease of Suidae, i.e., domestic pigs and wild boars, caused by African swine fever virus (ASFV). The development of cross-protective vaccines against ASF is imperative for effective disease control, particularly in regions where ASF is endemic, potentially featuring multiple circulating ASFV isolates. The investigation of non-hemadsorbing naturally attenuated isolates and laboratory recombinant strains with a deletion in the EP402R gene has attracted interest. Our study aimed to assess the impacts of various administration routes and doses of the naturally attenuated ASFV-PSA-1NH (immunotype IV, genotype I) isolate on the manifestation of clinical signs of ASF and the level of protection against the heterologous ASFV-Stavropol 01/08 strain (seroimmunotype VIII, genotype II). The results demonstrated that the intranasal administration of a low dose of ASFV-PSA-1NH to pigs minimized the clinical signs of ASF and established a high level of protection against the heterologous strain ASFV-Stavropol 01/08. Despite the challenges in standardizing the dosage for intranasal administration, this approach appears as a viable alternative in ASF vaccination.
- Subjects
AFRICAN swine fever; AFRICAN swine fever virus; INTRANASAL administration; SWINE; WILD boar; HEMORRHAGIC diseases; SWINE farms
- Publication
Animals (2076-2615), 2024, Vol 14, Issue 9, p1277
- ISSN
2076-2615
- Publication type
Article
- DOI
10.3390/ani14091277